Business News • MarketWire • ObsEva SA Announces CHF 32 Million Series A Funding From Leading Venture Capital Firms and a License Agreement With Merck Serono

ObsEva SA Announces CHF 32 Million Series A Funding From Leading Venture Capital Firms and a License Agreement With Merck Serono

ObsEva SA Announces CHF 32 Million Series A Funding From Leading Venture Capital Firms and a License Agreement With Merck Serono

GENEVA--(Marketwired - Aug 29, 2013) - ObsEva today announced the closing of a CHF 32 million Series-A financing round (EUR 25.6 million). The Series A financing round was led by Sofinnova Partners, and co-led by Sofinnova Ventures and Novo A/S. Concurrently, ObsEva signed a licensing agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, under which Merck Serono will grant ObsEva worldwide development and commercialization rights to certain Merck Serono compounds in the field of preterm labor. The details of the agreement are not being disclosed. The funding will allow ObsEva to undertake the development of these compounds.

View More : http://www.marketwire.com/mw/release.do?id=1825600&sourceType=3

Releted News by marketwire